Influenza cases

STO-REC-STAT01M2KJT2 National
1 billion
estimate

Global · 2026

Influenza cases stood at 1 billion in 2026 (GSK).

Original source
Publisher
GSK
Authority tier
T2 National
Locator
About seasonal flu
Retrieved
15 Sep 2026
Status
Verified

What the source says

Seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths.

Verbatim extraction verified: The figure 1 billion is directly attested in the quoted passage (About seasonal flu).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
GSK. (2026). GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF
MLA
GSK. "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data." 2026, https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF.
Chicago
GSK. "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data." 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF.
BibTeX
@misc{gsk2026influenzabjmggf, author = {{GSK}}, title = {GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STAT01M2KJ T2 National

Primary Source

Publisher
GSK · homepage ↗
Authority tier
Tier 2 · National Official
Report
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
Type
Press release
Published
Locator
About seasonal flu
Retrieved
15 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
15 September 2026
Last revision
15 September 2026
Archival URI
/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF